COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER

被引：0
|
作者：
Guan, X. [1 ]
Li, H. C. [1 ]
Xia, Y. [2 ]
Yang, Q. [2 ]
Ma, A. X. [1 ]
机构：
[1] China Pharmaceut Univ, Nanjing 32, Peoples R China
[2] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE197
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer
    Guan, X.
    Li, H-C.
    Chen, Q-J.
    Hua, B.
    Li, J-J.
    Ma, F.
    Wang, Y-S.
    Xu, H.
    Liu, C.
    Yang, Q.
    Ma, A-X.
    ANNALS OF ONCOLOGY, 2021, 32 : S45 - S45
  • [2] Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
    Yang, Jiangping
    Han, Jiaqi
    Zhang, Yalan
    Muhetaer, Muhelisa
    Chen, Nianyong
    Yan, Xi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
    Fonseca Magalhaes Filho, Marcos Aurelio
    Aguiar, Pedro Nazareth, Jr.
    Mascarenhas Neves, Milena Brachmans
    Lopes, Gilberto de Lima, Jr.
    del Giglio, Auro
    EINSTEIN-SAO PAULO, 2022, 20 : eGS6655
  • [4] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [5] A COST-EFFECTIVESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN PORTUGAL
    Silva Miguel, L.
    Pinheiro, B.
    Lopes, R.
    Revil, C.
    Monteiro, I
    Borges, M.
    VALUE IN HEALTH, 2022, 25 (01) : S69 - S70
  • [6] Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting
    Shanshan Hu
    Yilai Wu
    Jiajie Luan
    Shuowen Wang
    Guorong Fan
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 17933 - 17942
  • [7] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE FOR THE ADJUVANT TREAT OF PATIENTS WITH RESIDUAL INVASIVE HER2+EARLY BREAST CANCER IN GREECE
    Naoum, V
    Antonaki, M.
    Kakouros, M.
    Hansen, S. A.
    Ouzounelli, M.
    Tziarou, N.
    VALUE IN HEALTH, 2022, 25 (12) : S173 - S173
  • [8] Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer
    Konishi, Takaaki
    Fujiogi, Michimasa
    Michihata, Nobuaki
    Ohbe, Hiroyuki
    Matsui, Hiroki
    Fushimi, Kiyohide
    Tanabe, Masahiko
    Seto, Yasuyuki
    Yasunaga, Hideo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1115 - 1123
  • [9] Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting
    Hu, Shanshan
    Wu, Yilai
    Luan, Jiajie
    Wang, Shuowen
    Fan, Guorong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (20) : 17933 - 17942
  • [10] Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
    Geyer Jr, Charles E.
    Untch, Michael
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    D'Hondt, Veronique
    Conlin, Alison K.
    Guarneri, Valentina
    Wapnir, Irene L.
    Jackisch, Christian
    Arce-Salinas, Claudia
    Fasching, Peter A.
    Digiovanna, Michael P.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Bonnefoi, Herve R.
    Hennessy, Bryan T.
    Stamatovic, Ljiljana
    Castro-Salguero, Hugo
    Brufsky, Adam M.
    Knott, Adam
    Siddiqui, Asna
    Lambertini, Chiara
    Boulet, Thomas
    Nyawira, Beatrice
    Restuccia, Eleonora
    Loibl, Sibylle
    KATHERINE Study Grp
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
12345